Resources from the same session
LBA4 - Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
Presenter: Peter Schmid
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA4
Presenter: Marleen Kok
Session: Presidential Symposium II: Practice-changing trials
Resources:
Slides
Webcast
231O - Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial
Presenter: Sofia Rivera
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Invited Discussant 231O
Presenter: Charlotte Coles
Session: Presidential Symposium II: Practice-changing trials
Resources:
Slides
Webcast
LBA5 - A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
Presenter: Thomas Powles
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Presidential Symposium II: Practice-changing trials
Resources:
Webcast